Piperlongumine and its analogs down-regulate expression of c-Met in renal cell carcinoma

被引:34
作者
Golovine, Konstantin [1 ]
Makhov, Peter [1 ]
Naito, Sei [1 ]
Raiyani, Henish [1 ]
Tomaszewski, Jeffrey [2 ]
Mehrazin, Reza [2 ]
Tulin, Alexei [3 ]
Kutikov, Alexander [2 ]
Uzzo, Robert G. [2 ]
Kolenko, Vladimir M. [1 ]
机构
[1] Fox Chase Canc Ctr, Canc Biol Program, Philadelphia, PA 19111 USA
[2] Fox Chase Canc Ctr, Div Urol Oncol, Dept Surg, Philadelphia, PA 19111 USA
[3] Fox Chase Canc Ctr, Canc Epigenet Program, Philadelphia, PA 19111 USA
基金
美国国家卫生研究院;
关键词
c-Met; cancer; piperlongumine; renal; ROS; PROSTATE-CANCER CELLS; FACTOR-KAPPA-B; TIVANTINIB ARQ 197; SIGNALING PATHWAY; KIDNEY CANCER; IN-VIVO; RESISTANCE; INHIBITORS; TARGET; ROS;
D O I
10.1080/15384047.2015.1026511
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The c-Met protein, a transmembrane receptor tyrosine kinase, is the product of a proto-oncogene. Its only known ligand, hepatocyte growth factor (HGF), regulates cell growth, motility, migration, invasion, proliferation, and angiogenesis. The aberrant expression of c-Met is often associated with poor prognosis in multiple cancers, including renal cell carcinoma (RCC). Silencing or inactivation of c-Met leads to decreased viability of cancer cells, thereby making ablation of c-Met signaling an attractive concept for developing novel strategies for the treatment of renal tumors. Naturally-occurring products or substances are the most consistent source of drug development. As such, we investigated the functional impact of piperlongumine (PL), a naturally occurring alkaloid present in the Long pepper (Piper longum) on c-Met expression in RCC cells and demonstrated that PL and its analogs rapidly reduce c-Met protein and RNA levels in RCC cells via ROS-dependent mechanism. PL-mediated c-Met depletion coincided with the inhibition of downstream c-Met signaling; namely Erk/MAPK, STAT3, NF-B and Akt/mTOR. As such, PL and PL analogs hold promise as potential therapeutic agents for the treatment of metastatic RCC and the prevention of postoperative RCC recurrence.
引用
收藏
页码:743 / 749
页数:7
相关论文
共 50 条
  • [1] c-Met in chromophobe renal cell carcinoma
    Erlmeier, Franziska
    Ivanyi, Philipp
    Hartmann, Arndt
    Autenrieth, Michael
    Wiedemann, Max
    Weichert, Wilko
    Steffens, Sandra
    MEDICAL ONCOLOGY, 2017, 34 (02)
  • [2] c-Met expression in renal cell carcinoma with bone metastases
    Paiva, Rita Silva
    Gomes, Ines
    Casimiro, Sandra
    Fernandes, Isabel
    Costa, Luis
    JOURNAL OF BONE ONCOLOGY, 2020, 25
  • [3] c-Met in chromophobe renal cell carcinoma
    Franziska Erlmeier
    Philipp Ivanyi
    Arndt Hartmann
    Michael Autenrieth
    Max Wiedemann
    Wilko Weichert
    Sandra Steffens
    Medical Oncology, 2017, 34
  • [4] Expression and clinical significance of c-Met in advanced esophageal squamous cell carcinoma
    Xu, Yingying
    Peng, Zhi
    Li, Zhongwu
    Lu, Ming
    Gao, Jing
    Li, Yilin
    Li, Yanyan
    Shen, Lin
    BMC CANCER, 2015, 15
  • [5] Biological significance of c-met over expression in papillary renal cell carcinoma
    Sweeney, P
    El-Naggar, AK
    Lin, SH
    Pisters, LL
    JOURNAL OF UROLOGY, 2002, 168 (01) : 51 - 55
  • [6] c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma
    Gibney, G. T.
    Aziz, S. A.
    Camp, R. L.
    Conrad, P.
    Schwartz, B. E.
    Chen, C. R.
    Kelly, W. K.
    Kluger, H. M.
    ANNALS OF ONCOLOGY, 2013, 24 (02) : 343 - 349
  • [7] Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression
    Lalani, Aly-Khan A.
    Gray, Kathryn P.
    Albiges, Laurence
    Callea, Marcella
    Pignon, Jean-Christophe
    Pal, Soumitro
    Gupta, Mamta
    Bhatt, Rupal S.
    McDermott, David F.
    Atkins, Michael B.
    Vande Woude, G. F.
    Harshman, Lauren C.
    Choueiri, Toni K.
    Signoretti, Sabina
    ONCOTARGET, 2017, 8 (61) : 103428 - 103436
  • [8] Correlation of c-Met Expression and Outcome in Patients With Renal Cell Carcinoma Treated With Sunitinib
    Peltola, Katriina Johanna
    Penttila, Patrick
    Rautiola, Juhana
    Joensuu, Heikki
    Hanninen, Erkki
    Ristimaki, Ari
    Bono, Petri
    CLINICAL GENITOURINARY CANCER, 2017, 15 (04) : 487 - 494
  • [9] c-MET Oncogene in Renal Cell Carcinomas
    Erlmeier, F.
    Weichert, W.
    Autenrieth, M.
    Ivanyi, P.
    Hartmann, A.
    Steffens, S.
    AKTUELLE UROLOGIE, 2016, 47 (06) : 475 - 479
  • [10] Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression
    Fu, Rongdang
    Jiang, Shaotao
    Li, Jieyuan
    Chen, Huanwei
    Zhang, Xiaohong
    MEDICAL ONCOLOGY, 2020, 37 (04)